{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"24.2","upperLimit":"49.4","value":"36.1"},{"groupId":"OG001","lowerLimit":"8.7","upperLimit":"49.1","value":"25.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"20"}],"units":"Participants"}],"description":"Measure of clinical benefit, defined as the percentage of complete response (CR), partial response (PR), and stable disease (SD) beyond 16 weeks.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with a deleterious mutation in one of the following genes: BRCA1, BRCA2, PALB2, RAD51C, or RAD51D.","id":"OG000","title":"Rucaparib Cohort A"},{"description":"Participants with a deleterious mutation in one of the following genes: BARD1, BRIP1, FANCA, NBN, RAD51, or RAD51B.","id":"OG001","title":"Rucaparib Cohort B"}],"paramType":"NUMBER","populationDescription":"Efficacy population - all participants evaluable for response by RECIST v1.1 (or modified RECIST v1.1/PCWG3 for mCRPC participants).","reportingStatus":"POSTED","timeFrame":"From first dose of study drug until disease progression (up to approximately 2 years)","title":"Disease Control Rate","type":"SECONDARY","unitOfMeasure":"percentage of participants"}